The potential impact of CAR T-cell treatment delays on society

To date, breakthrough chimeric antigen receptor (CAR) T-cell therapies, such as tisagenlecleucel, indicated for pediatric acute lymphoblastic leukemia (pALL) and diffuse large B-cell lymphoma (DLBCL), and axicabtagene ciloleucel, indicated for DLBCL, although clinically effective, have been limited...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The American journal of managed care 2019-08, Vol.25 (8), p.379-386
Hauptverfasser:	Thornton Snider, Julia, Brauer, Michelle, Kee, Rebecca, Batt, Katharine, Karaca-Mandic, Pinar, Zhang, Jie, Goldman, Dana P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipocytes Antigens Health administration Leukemia Lymphoma Medical treatment Patients Pediatrics Production costs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!